Evidence map›Paper›PMID 32966814›Full record

ArticleBiochemical pharmacology2020

AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication.

Jonathan O Rayner, Rosemary A Roberts, Jin Kim, Andrew Poklepovic, Jane L Roberts, Laurence Booth, Paul Dent

Open access · greenAbstract read
In one paragraph

Article in Biochemical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 58 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Nature's cryptographic codebreakerFrontiers in microbiology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. COVID-19, Obesity, and GRP78: Unraveling the Pathological Link.Journal of obesity & metabolic syndrome · 2023
    Review
  12. Review
  13. COVID-19-related hyperglycemia is associated with infection of hepatocytes and stimulation of gluconeogenesis.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  14. Article
  15. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jonathan O RaynerDepartment of Microbiology and Immunology, Laboratory of Infectious Diseases, University of South Alabama, Mobile, AL 36688-0002, United States.
Rosemary A RobertsDepartment of Microbiology and Immunology, Laboratory of Infectious Diseases, University of South Alabama, Mobile, AL 36688-0002, United States.
Jin KimDepartment of Microbiology and Immunology, Laboratory of Infectious Diseases, University of South Alabama, Mobile, AL 36688-0002, United States.
Andrew PoklepovicDepartments of Medicine, Virginia Commonwealth University, Richmond, VA 23298-0035, United States.
Jane L RobertsDepartments of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA 23298-0035, United States.
Laurence BoothDepartments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298-0035, United States.
Paul DentDepartments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298-0035, United States. Electronic address: paul.dent@vcuhealth.org.
Virginia Commonwealth University · USUniversity of South Alabama · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AR12 is a derivative of celecoxib which no-longer acts against COX2 but instead inhibits the ATPase activity of multiple chaperone proteins, in particular GRP78. GRP78 acts as a sensor of endoplasmic reticulum stress and is an essential chaperone required for the life cycle of all mammalian viruses. We and others previously demonstrated in vitro and in vivo that AR12 increases autophagosome formation and autophagic flux, enhances virus protein degradation, preventing virus reproduction, and prolonging the survival of infected animals. In this report, we determined whether AR12 could act against SARS-CoV-2. In a dose-dependent fashion AR12 inhibited SARS-CoV-2 spike protein expression in transfected or infected cells. AR12 suppressed the production of infectious virions via autophagosome formation, which was also associated with degradation of GRP78. After AR12 exposure, the colocalization of GRP78 with spike protein was reduced. Knock down of eIF2α prevented AR12-induced spike degradation and knock down of Beclin1 or ATG5 caused the spike protein to localize in LAMP2+ vesicles without apparent degradation. HCT116 cells expressing ATG16L1 T300, found in the majority of persons of non-European descent, particularly from Africa, expressed greater amounts of GRP78 and SARS-CoV-2 receptor angiotensin converting enzyme 2 compared to ATG16L1 A300, predominantly found in Europeans, suggestive that ATG16L1 T300 expression may be associated with a greater ability to be infected and to reproduce SARS-CoV-2. In conclusion, our findings demonstrate that AR12 represents a clinically relevant anti-viral drug for the treatment of SARS-CoV-2.

Indexed as

AnimalsAntiviral AgentsCell Line, TumorChlorocebus aethiopsCOVID-19 Drug TreatmentEndoplasmic Reticulum Chaperone BiPFemaleHeat-Shock ProteinsHumansPyrazolesSARS-CoV-2Spike Glycoprotein, CoronavirusSulfonamidesVero CellsVirus ReplicationAntiviral AgentsEndoplasmic Reticulum Chaperone BiPHeat-Shock ProteinsHSPA5 protein, humanOSU 03012PyrazolesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2SulfonamidesAR12ATG16L1AutophagyOSU-03012SARS-CoV-2Spike proteinVirus

Identifiers

PMID32966814
PMCPMC7502229
OpenAlexW3087700599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.